EV/EBITDA Multiple: Metsera Corp (MTSR)

Corporate company logo of metsera.com (MTSR)

Metsera Inc (MTSR) enjoys high investor confidence due to its robust scientific foundation and ambitions in obesity therapy. Its proprietary peptide development platform creates a strong patent barrier, as seen in the enterprise value to EBITDA ratio on GURU.Markets, where 0.00 determines the current value of the metric. The operating model relies on external partners for drug manufacturing and distribution.

MTSR (Metsera, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/29/2025

metsera.com (MTSR) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Metsera Corp|MTSR - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Metsera Therapeutics|MTSR - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Metsera|MTSR - Total Net Assets|Market Capitalization to Book Value Ratio metsera.com|MTSR - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Metsera Inc|MTSR - Long-Term Debt to Equity|Short-Term Debt to Equity Metsera|MTSR - Company Cumulative Debt|Debt to Book Capitalization Ratio Metsera Therapeutics|MTSR - Company Long-Term Debt|Company Short-Term Debts Metsera|Quick Liquidity metsera.com
- net income and valuation multiples indicators:
MTSR - Net Financial Result|Expected Profit Metsera Inc|MTSR - Price to Earnings Ratio|Future Price to Earnings Metsera Inc|MTSR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Metsera Therapeutics|MTSR - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Metsera|MTSR - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months metsera.com|MTSR - Expected net earnings per share growth this year|Earnings growth forecast for next year Metsera Inc
Initial company analysis:MTSR (Metsera Corp)
Product sample of Metsera

For Metsera Inc (MTSR), which competes in the high-cost obesity drug segment, it is critical to align market value with actual operational efficiency. By analyzing the EV/EBITDA multiple, an investor can see the ratio of total enterprise value (market capitalization and debt) to earnings before interest, taxes, depreciation, and amortization, which allows for an assessment of whether the asset is overvalued amid an aggressive clinical trial race.

Who Metsera Inc competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MLTX: Enterprise Value to Operating Income Before Depreciation Ratio|CRNX (Crinetics Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma Corp|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (amicusrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioAge Labs, Inc. BIOA|BMEA - Enterprise Value to EBITDA Ratio|Quince - EV/EBITDA Multiple|Company Value to EBITDA Fractyl Health Inc.|VTVT (vtvtherapeutics.com) - Enterprise Value to EBITDA Ratio|ATPC: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluristem Therapeutics|Synlogic Corp (SYBX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LPCN|MTNB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences SPRB|Business Value to Operating Income Before Depreciation GLTO|Carmell Corporation - EV/EBITDA Multiple|LUMO - EV/EBITDA Multiple|ONVO (Organovo) - Enterprise Value to EBITDA Ratio|Radius Recycling Inc. - Business Value to Operating Income Before Depreciation